Belviq was developed by San Diego-based drugmaker Arena Pharmaceuticals and was approved by the FDA in 2012. Arena later sold it to Eisai, and the drugmaker has continued selling it in the U.S. market.
The FDA said Feb. 13 it found an increased cancer risk linked to Belviq from a clinical trial that was started after the drug received approval. The agency recommended people stop using Belviq immediately and for it to be removed from the market.
The FDA said the cancer risk increases the longer the drug is taken.
Read the full news release here.
More articles on pharmacy:
Why physicians are fighting BCBS plan requiring use of mail-order pharmacies
Foreign governments are using US research, manipulating drug prices, White House study claims
Chain drugstores under probe in Oklahoma after claims of inadequate pharmacy staffing
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
